АНТИГЕНЫ ПОВЕРХНОСТНЫХ СТРУКТУР HAEMOPHILUS INFLUENZAE КАК ПЕРСПЕКТИВНЫЕ КАНДИДАТ-ВАКЦИНЫ

Q3 Medicine

Zhurnal mikrobiologii, epidemiologii, i immunobiologii Pub Date : 2017-08-28 DOI:10.36233/0372-9311-2017-4-82-90

Н. Н. Овенко, Н. Е. Ястребова

{"title":"АНТИГЕНЫ ПОВЕРХНОСТНЫХ СТРУКТУР HAEMOPHILUS INFLUENZAE КАК ПЕРСПЕКТИВНЫЕ КАНДИДАТ-ВАКЦИНЫ","authors":"Н. Н. Овенко, Н. Е. Ястребова","doi":"10.36233/0372-9311-2017-4-82-90","DOIUrl":null,"url":null,"abstract":"Despite long and successful use of Haemophilus influenzae b (Hib) vaccine, production of the vaccine against non-typed strains of Haemophilus influenzae (NTHi) is only being developed. Difficulties of this work are determined by features of NTHi compared with Hib: lack of polysaccharide capsule, high level of antigenic heterogeneity and specialties of pathogenesis development that includes spread through the organism from mucosa of the respiratory tract. Currently, 15 surface structures of NTHi are being actively studied with the aim of creating the vaccine. PE, P2, P6, PD proteins, outer membrane vesicles (OMVs) and others are among them. Only PD protein currently has practical application, that was used as a carrier with antigenic function in conjugated polysaccharide vaccines against pneumonia (Prevenar; PHiD-CV). Vaccination with these preparations allowed to reduce the total morbidity with acute rhinitis on children by 33 - 52%. However, this result can not be examined as final, thus, research and approbation of the vaccine-candidates continues.","PeriodicalId":24020,"journal":{"name":"Zhurnal mikrobiologii, epidemiologii, i immunobiologii","volume":"21 1","pages":"82-90"},"PeriodicalIF":0.0000,"publicationDate":"2017-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhurnal mikrobiologii, epidemiologii, i immunobiologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36233/0372-9311-2017-4-82-90","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

Despite long and successful use of Haemophilus influenzae b (Hib) vaccine, production of the vaccine against non-typed strains of Haemophilus influenzae (NTHi) is only being developed. Difficulties of this work are determined by features of NTHi compared with Hib: lack of polysaccharide capsule, high level of antigenic heterogeneity and specialties of pathogenesis development that includes spread through the organism from mucosa of the respiratory tract. Currently, 15 surface structures of NTHi are being actively studied with the aim of creating the vaccine. PE, P2, P6, PD proteins, outer membrane vesicles (OMVs) and others are among them. Only PD protein currently has practical application, that was used as a carrier with antigenic function in conjugated polysaccharide vaccines against pneumonia (Prevenar; PHiD-CV). Vaccination with these preparations allowed to reduce the total morbidity with acute rhinitis on children by 33 - 52%. However, this result can not be examined as final, thus, research and approbation of the vaccine-candidates continues.

查看原文本刊更多论文

HAEMOPHILUS INFLUENZAE表面结构的抗原作为潜在的疫苗候选人。

尽管长期成功地使用了b型流感嗜血杆菌(Hib)疫苗，但针对流感嗜血杆菌(NTHi)非分型菌株的疫苗的生产只是在开发中。与Hib相比，NTHi的特点决定了这项工作的困难:缺乏多糖胶囊，抗原异质性高，发病机制发展的特殊性，包括从呼吸道粘膜通过生物体传播。目前，正在积极研究NTHi的15种表面结构，目的是制造疫苗。其中包括PE、P2、P6、PD蛋白、外膜囊泡(omv)等。目前只有PD蛋白有实际应用，作为具有抗原功能的载体应用于肺炎结合多糖疫苗(Prevenar;PHiD-CV)。接种这些制剂可使儿童急性鼻炎的总发病率降低33 - 52%。然而，这一结果不能被视为最终结果，因此，候选疫苗的研究和批准仍在继续。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊